| CAS |
115-33-3 |
| Chinese Name |
双醋酚丁 |
| English Name |
Oxyphenisatin Acetate |
| Synonyms |
双醋酚丁;Izafenin;Diphesatine;Brocatine; |
| Molecular Formula |
C24H19NO5 |
| Molecular Weight |
401.41 |
| Solubility |
Soluble in DMSO |
| Purity |
≥98% |
| Appearance |
White to off-white Solid |
| Storage |
Powder:-20℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| EC |
EINECS 204-083-6 |
| MDL |
MFCD00022793 |
| SMILES |
CC(=O)OC1=CC=C(C=C1)C2(C3=CC=CC=C3NC2=O)C4=CC=C(C=C4)OC(=O)C |
| InChIKey |
PHPUXYRXPHEJDF-UHFFFAOYSA-N |
| InChI |
InChI=1S/C24H19NO5/c1-15(26)29-19-11-7-17(8-12-19)24(18-9-13-20(14-10-18)30-16(2)27)21-5-3-4-6-22(21)25-23(24)28/h3-14H,1-2H3,(H,25,28) |
| PubChem CID |
8269 |
| Target Point |
Others |
| Passage |
Others |
| Background |
Oxyphenisatin Acetate is a biologically or chemically active compound. |
| Biological Activity |
Oxphenisatin Acetate inhibits the growth of breast cancer cells by inhibiting translation, rapid phosphorylation. The pathways involved in apoptosis induction, starvation responses, and RNA/protein metabolism. Oxphenisatin Acetate also results in mitochondrial dysfunction.[1] |
| In Vitro |
Oxyphenisatin acetate inhibits the growth of the breast cancer cell lines MCF7，T47D，HS578T，and MDA-MB-468. In the estrogen receptor(ER)positive MCF7 and T47D cells，oxyphenisatin acetate induces TNFα expression and TNFR1 degradation，indicating autocrine receptor-mediated apoptosis in these lines. Ten micromoles per liter Oxyphenisatin acetate treatment results in autophagy and mitochondrial dysfunction[1].In the estrogen receptor(ER)positive MCF7 and T47D cells，OXY induced TNFα expression and TNFR1 degradation，indicating autocrine receptor-mediated apoptosis in these lines. Lastly，in an MCF7 xenograft model，OXY delivered intraperitoneally inhibited tumor growth，accompanied by phosphorylation of eIF2α and degradation of TNFR1. OXY induces a multifaceted cell starvation response，which ultimately induces programmed cell death[1]. |
| In Vivo |
Oxyphenisatin acetate(300 mg/kg，i.p.)delivers intraperitoneally inhibited tumor growth，accompanied by phosphorylation of eIF2α and degradation of TNFR1 in an MCF7 xenograft model[1]. |
| Cell Experiment |
Total RNA was isolated from MCF7 cells treated with 10 μmol/L OXY for 24 h and the microarray procedure performed as described previously using the GeneChip Human U133 plus 2.0 array . Pairwise analysis was performed on control versus treated arrays using a fivefold change cutoff，<0.01 adjusted P-value，GC-RMA normalization with Benjamini–Hochberg false discovery estimation[1]. |
| Animal Experiment |
Assessment in several other tumor models demonstrates tolerability with oxyphenisatin acetate at 300 mg/kg given once daily or 200 mg/kg given twice daily. For the MCF-7 study treatments are administered on an exact body weight basis using dose volumes of 1-2 mL/kg body weight. The vehicle control receives 100% DMSO. The treated group receives 300 mg/kg oxyphenisatin acetate once daily for a total of 10 days，followed by a 3 day rest and an additional 6 days of dosing. The dose solutions are prepared in 100% DMSO，aliquoted and stored frozen until used. The mice are monitored for a total of 52 days with treatment initiation occurring on day 27 posttumor implantation[1]. |
| Data Literature Source |
[1]. Morrison BL，et al. Oxyphenisatin acetate (NSC 59687) triggers a cell starvation response leading to autophagy，mitochondrial dysfunction，and autocrine TNFα-mediated apoptosis. Cancer Med. 2013 Oct;2(5):687-700. |
| Unit |
Bottle |
| Specification |
5mg 10mg 25mg |
English
中文
Manual Download
